RAPP: Rapport Pharma Analyst Consensus Forecast

Rapport Therapeutics, Inc. (RAPP) brings together leading neuroscience experts to develop precision CNS therapies, leveraging robust R&D capabilities. The price action shown below correlates with the efficiency of biomaterial delivery between research centers, with the current metric standing at 64.10. Strong market optimism and confidence in epilepsy treatment methods establish the company as a promising innovator in its field.

Rapport Corp (RAPP) - Price Target Chart from 06/08/2024 to 11/11/2026

Analytical breakdowns for Rapport Pharma (RAPP)

- share price and consensus valuation forecast:

Price Performance Chart rapportrx.com|RAPP - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization Rapport Pharma|RAPP - Total Company Value

- balance sheet equity data:

Share Book Value Rapport Therapeutics|RAPP - Company Book Value|Market Capitalization to Net Assets rapportrx.com|RAPP - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

Aggregate Debt to Equity Rapport Therapeutics, Inc.|RAPP - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Rapport Corp|RAPP - Company Aggregate Debts|Debts to Book Capitalization Rapport Pharma|RAPP - Company Long-Term Debt|Company Short-Term Loans and Borrowings Rapport Therapeutics|Quick Liquidity Indicator rapportrx.com

- earnings and valuation multiples indicators:

RAPP - Net Profit|Projected Future Earnings Rapport Therapeutics, Inc.|RAPP - Price to Earnings Ratio|Future Price to Earnings Multiple Rapport Therapeutics Inc|RAPP - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Rapport Pharma|RAPP - Operating profit EBITDA|Net earnings per one share for the last twelve months Rapport Therapeutics|RAPP - Net earnings per share for the last 12 months|Quarterly EPS earnings growth rapportrx.com|RAPP - Earnings per share growth in current year|Expected earnings per share trend next year Rapport Therapeutics, Inc.

General company analysis:RAPP rapportrx.com

As a portfolio manager, I view this indicator as an aggregator of professional expectations regarding the asset's value. The metric calculates the arithmetic mean of expert price targets, reflecting the fundamental potential for growth or correction. By analyzing the consensus target price trend, an investor can identify an objective valuation vector for the business. The current value of 64.10 confirms the market bet on Rapport Therapeutics, Inc. (RAPP), driven by high demand for innovative molecules for the therapy of neurological pathologies.

Competitors of Rapport Therapeutics, Inc.